华润医药拟再度为核心子公司华润医药商业启动北交所公开募资预挂牌，尚无发行规模与约束性协议

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited
take no responsibility for the contents of this announcement, make no representation as to
its accuracy or completeness and expressly disclaim any liability whatsoever for any loss
howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION
POTENTIAL ISSUANCE OF SHARES BY
CR PHARMACEUTICAL COMMERCIAL
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited (the ‘‘Listing Rules’’) and the
Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the
Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the ‘‘SFO’’).
COMMENCEMENT OF PRE-BIDDING PROCESS FOR THE POTENTIAL
ISSUANCE BY CR PHARMACEUTICAL COMMERCIAL
The board of directors (the ‘‘Board’’) of China Resources Pharmaceutical Group Limited
(the ‘‘Company’’) hereby announces that China Resources Pharmaceutical Commercial
Group
Company
Limited
(華潤醫藥商業集團有限公司)
(‘‘CR
Pharmaceutical
Commercial’’), a non-wholly-owned subsidiary of the Company, has proposed to issue new
shares by way of public bidding via a legally established equity exchange in accordance
with the relevant regulations of the Measures for the Supervision and Administration of the
Trading of State-Owned Assets of Enterprises (企業國有資產交易監督管理辦法) (the
‘‘Potential Issuance’’). The number of new shares to be issued and the amount of proceeds
to be raised under the Potential Issuance will be determined in due course having considered
various factors including the market conditions.
On 16 October 2026, the pre-bidding process in relation to the Potential Issuance (the ‘‘PreBidding Process’’) commenced via the China Beijing Equity Exchange. CR Pharmaceutical
Commercial has published an application form for pre-disclosure of information for capital
raising on 16 October 2026 in relation to the Pre-Bidding Process (the ‘‘Application’’) on
the website of the China Beijing Equity Exchange. Full text of the Application is available
on the website of the China Beijing Equity Exchange at www.cbex.com.cn. Following the
completion of the Pre-Bidding Process, the Potential Issuance remains subject to the formal
public bidding process on the China Beijing Equity Exchange.

–1–

The Board wishes to emphasize that no binding agreement with respect to the Potential
Issuance has been entered into by CR Pharmaceutical Commercial as at the date of this
announcement, and there is no assurance that any definitive transaction with respect to the
Potential Issuance will materialize. The Company will make further announcement(s) in
compliance with the Listing Rules and/or Part XIVA of the SFO as and when appropriate or
required.
CR Pharmaceutical Commercial may or may not enter into a binding agreement with
respect to the Potential Issuance, and even if it decides to do so, the Potential Issuance
may be subject to fulfilment of closing conditions and may or may not proceed to
completion for various reasons. Shareholders of the Company and potential investors
are advised to exercise caution when dealing in the securities of the Company.
For ease of reference, the names of the PRC established companies or entities have been
included in this announcement in both the Chinese and English languages, and in the event
of any inconsistency, the Chinese version shall prevail.
By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman
PRC, 16 October 2026
As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman
and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm.
Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang
as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian
and Mr. Shi Luwen as independent non-executive Directors.

–2–